Tasurgratinib
C32H37N5O6 — CID 78323434
View drug profile → tasurgratinibData last refreshed: (MolForge compound catalog, from PubChem)
About Tasurgratinib
Tasurgratinib (PubChem CID 78323434) has the molecular formula C32H37N5O6 and a molecular weight of 587.68 g/mol. Its IUPAC name is 5-[[2-[[4-[1-(2-hydroxyethyl)piperidin-4-yl]benzoyl]amino]-4-pyridinyl]oxy]-6-(2-methoxyethoxy)-N-methylindole-1-carboxamide.
Molecular Properties
| Compound Name | Tasurgratinib |
|---|---|
| PubChem CID | 78323434 |
| Molecular Formula | C32H37N5O6 |
| Molecular Weight | 587.68 g/mol |
| Exact Mass | 587.27 |
| IUPAC Name | 5-[[2-[[4-[1-(2-hydroxyethyl)piperidin-4-yl]benzoyl]amino]-4-pyridinyl]oxy]-6-(2-methoxyethoxy)-N-methylindole-1-carboxamide |
| SMILES | CNC(=O)n1ccc2cc(Oc3ccnc(NC(=O)c4ccc(C5CCN(CCO)CC5)cc4)c3)c(OCCOC)cc21 |
| InChI | InChI=1S/C32H37N5O6/c1-33-32(40)37-14-10-25-19-29(28(21-27(25)37)42-18-17-41-2)43-26-7-11-34-30(20-26)35-31(39)24-5-3-22(4-6-24)23-8-12-36(13-9-23)15-16-38/h3-7,10-11,14,19-21,23,38H,8-9,12-13,15-18H2,1-2H3,(H,33,40)(H,34,35,39) |
| InChIKey | IBHOLSBDZMIPPT-UHFFFAOYSA-N |
| XLogP | 4.47 |
| TPSA | 127.18 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 11 |
| Heavy Atoms | 43 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 587.68 |
| LogP ≤ 5 | 4.47 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 9 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'} |
|---|
Related Compounds
Frequently Asked Questions
Browse: Molecules: T · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 78323434 — identifiers, structure, computed properties (public domain)
- DrugCentral drug card 5835 — approved-drug record (CC BY-SA 4.0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.